AN2 Therapeutics, a biopharmaceutical company, has made the decision to voluntarily pause Phase 3 enrollment in its Phase 2/3 clinical trial for the treatment-refractory MAC lung disease. This pause is pending further data review. Trial Details The double-blind trial consists of two arms. One arm compares epetraborole plus optimized background regimen (OBR), while the other arm … [Read more...] about AN2 Therapeutics Pauses Phase 3 Enrollment in Clinical Trial
clinical trial
Moleculin Biotech Announces Positive Results From Phase 1 Clinical Trial of Annamycin
Moleculin Biotech, a clinical stage pharmaceutical company, has reported encouraging data from a Phase 1 clinical trial of their drug, annamycin. The study revealed no evidence of cardiotoxicity in the subjects treated with the drug. As a result, Moleculin Biotech's shares soared by 17% to 72 cents. Despite experiencing a 33% decline in the stock value this year, this recent … [Read more...] about Moleculin Biotech Announces Positive Results From Phase 1 Clinical Trial of Annamycin
